Granite Creek Capital Partners, L.L.C. Announces an Investment in Royal Biologics

JERSEY CITY, N.J., June 27, 2019 /PRNewswire-PRWeb/ -- Granite Creek Capital Partners, L.L.C., a private investment firm that partners with businesses, has announced its investment in Royal Biologics, a medical device company focused on next-level regenerative medicine technologies. Royal Biologics is the first healthcare investment of Granite Creek's FlexCap II private investment fund.

Royal Biologics, a pioneering manufacturer and distributor of devices used in stem cell and other surgical procedures, develops, licenses, produces and distributes biologics, orthobiologics and orthopedic implant products. The company's overarching goal is the use patients' own bioactive cells to promote healing.

The Granite Creek investment will be strategically utilized to bring new talent to Royal Biologics, expand the company's operations, advance product development and innovations, and pursue strategic acquisitions. Jim Clark and Mark Radzik, Partners at Granite Creek, will serve on the Board of Royal Biologics.

As a result of its recently closed $200 million FlexCap II fund, Granite Creek is well positioned to invest in 15-20 companies engaged in manufacturing, business services, healthcare and agribusiness. Granite Creek engages with the leadership of its portfolio companies in meaningful ways and serves as a trusted advisor and partner to each company.

"Salvatore Leo and Demetri Soteropoulos, the founders and leaders of Royal Biologics, have built an exceptional business that stands out for its innovations and service," said Mark Radzik, Partner at Granite Creek. "We are proud to partner with such a results-driven organization and look forward to supporting the company's continued investments in its product portfolio, distribution network, and management team as it reaches its next stage of growth."

"We are very excited to partner with Granite Creek Capital Partners," said Salvatore Leo, CEO at Royal Biologics. "We feel their experience in healthcare and their track record of scaling businesses aligns with our core values for future expansion."

SOURCE Royal Biologics